Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...1011121314151617181920...401402»
  • ||||||||||  Review, Journal:  Myosteatosis: diagnostic significance and assessment by imaging approaches. (Pubmed Central) -  Nov 17, 2024   
    Additionally, emerging studies on artificial intelligence (AI) may provide further insights into quantification and automated assessment, including MRS analysis. In this review, we discuss the pathophysiological aspects of myosteatosis, all the current imaging techniques and recent advances in imaging assessment as potential biomarkers of myosteatosis, and the most common clinical conditions involved.
  • ||||||||||  Preclinical, Journal:  Lifelong dietary protein restriction induces denervation and skeletal muscle atrophy in mice. (Pubmed Central) -  Nov 16, 2024   
    These changes were accompanied by an increase in proteasome activity in skeletal muscle, with no significant alterations in oxidative stress or mitochondrial dynamics markers in skeletal muscle later in life. Thus, lifelong protein restriction may induce skeletal muscle atrophy through changes in peripheral nerves and neuromuscular junctions, potentially contributing to the early onset or exaggeration of sarcopenia.
  • ||||||||||  Journal:  Exploring the Intricate Nexus of Sarcopenia and Cognitive Impairment. (Pubmed Central) -  Nov 16, 2024   
    Exercise, nutritional, and cognitive interventions are significant as nonpharmacologic approaches in the treatment of sarcopenia and cognitive impairment. However, the specific mechanism of interaction between two diseases, biomarkers and effective therapeutic medications still has knowledge gaps that need to be further explored.
  • ||||||||||  Journal:  Circulating BMP-7 Level is Independent of Sarcopenia in Older Asian Adults. (Pubmed Central) -  Nov 16, 2024   
    Despite experimental evidence supporting BMP-7's role in muscle metabolism, this study found no significant association between serum BMP-7 levels and clinical indicators of muscle health in older adults. These findings challenge the utility of serum BMP-7 as a biomarker for sarcopenia in this demographic.
  • ||||||||||  Journal:  Ratio of red blood cell distribution width to albumin level and risk of mortality in sarcopenic obesity. (Pubmed Central) -  Nov 16, 2024   
    Moreover, in comparison to the baseline model lacking covariates, the AUC values of the joint model exhibited heightened levels at various time points. Therefore, We demonstrated that the RAR level is an independent prognostic factor for mortality risk in the American population with sarcopenic obesity, and it is reasonable to consider the RAR level as a simple and effective risk prediction tool.
  • ||||||||||  Journal:  Sarcopenia and sleep in individuals with chronic obstructive pulmonary disease. (Pubmed Central) -  Nov 16, 2024   
    Individuals with COPD and sarcopenia (as measured by handgrip strength) have worse objectively measured sleep outcomes. This was not the case regarding a self-reported perception of worse sleep quality, although there was weak-to-moderate association between handgrip strength and subjective sleep.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Pharmacological Treatment of Obesity in Older Adults. (Pubmed Central) -  Nov 16, 2024   
    We further discuss specific approaches to frequently represented phenotype of obesity in older adults, in particular sarcopenic obesity and rationale when to treat and how. In older adults with obesity there is a need for more drug trials focusing not only on weight loss, but also on geriatric endpoints including muscle mass preservation, bone quality and favourable fat distribution changes to get enough data for evidence-based recommendation on obesity treatment in this growing sub-population.
  • ||||||||||  Journal, Real-world evidence, Real-world:  Drug risks associated with sarcopenia: a real-world and GWAS study. (Pubmed Central) -  Nov 15, 2024   
    We find that metformin, aspirin, and acetaminophen are specifically noted for their potential to induce sarcopenia based on the analyses conducted. We perform signal mining for drug-associated sarcopenia events based on real-world data and provides certain guidance for the safe use of medications to prevent sarcopenia.
  • ||||||||||  Review, Journal:  Reactive oxygen species in age-related musculoskeletal decline: implications for nutritional intervention. (Pubmed Central) -  Nov 15, 2024   
    In muscle, this is reflected in an age-related attenuation of specific adaptations and responses to contractile activity that impacts the ability of skeletal muscle from ageing individuals to respond to exercise. These pathways provides potential targets for identification of logical interventions that may help maintain muscle mass and function during ageing.
  • ||||||||||  Review, Journal:  Rethinking Diabetes from the Perspective of Diverse Insulin Actions in Various Organs. (Pubmed Central) -  Nov 15, 2024   
    To cure diabetes, it is necessary to elucidate the whole picture of insulin actions including those other than metabolic actions in various tissues and to understand what disorders are caused by its reduction or excess. This article reviews diverse insulin actions in various organs and the effects of their deficiency on diabetes, its complications, and associated diseases.
  • ||||||||||  Journal:  Protein requirement in obesity. (Pubmed Central) -  Nov 15, 2024   
    During weight loss the rebuilding of the body is likely to need at least 1.2?g/kg body weight/d with a maximum weight of BMI 30, especially in the aged. Obesity might increase protein requirements, however being obese with a healthy and active lifestyle might result in normal protein requirements.
  • ||||||||||  Review, Journal:  Lost in translation: challenges of current pharmacotherapy for sarcopenia. (Pubmed Central) -  Nov 15, 2024   
    Although numerous interventions have been proposed to reduce sarcopenia, none has yet succeeded in clinical trials. This review evaluates the biological gap between recent clinical trials targeting sarcopenia and the preclinical studies on which they are based, and suggests an alternative approach to bridge the discrepancy.
  • ||||||||||  Biomarker, Journal:  Serum albumin as a biomarker of (nutritional status in) sarcopenia. (Pubmed Central) -  Nov 15, 2024   
    Older and obese adults at risk of malnutrition should be screened/diagnosed and treated early for sarcopenia. Prospective studies are needed for better/prompt management of relevant patients who are prone to significant morbidity and mortality.
  • ||||||||||  Review, Journal:  Bergamot (Citrus bergamia), a (Poly)Phenol-Rich Source for Improving Osteosarcopenic Obesity: A Systematic Review. (Pubmed Central) -  Nov 15, 2024   
    Furthermore, some studies have shown that bergamot extracts can improve the metabolic balance, endothelial function, and maximal oxygen uptake in athletes, highlighting their potential benefits for skeletal muscle health. Taken together, these results suggest that bergamot extracts, especially those rich in polyphenols, may be a valuable adjunct in the management of osteosarcopenic obesity and other associated clinical conditions involving pro-inflammatory effects on organs and tissues.
  • ||||||||||  Review, Journal:  Nutritional Interventions in Older, Frail Persons with Heart Failure-A Systematic Narrative Review. (Pubmed Central) -  Nov 15, 2024   
    The studies using protein supplementation, ONS or EN reported improvements on functional measures or body composition. Furthermore, the results from this review add to the evidence of the importance of combining nutritional support with physical activity to improve muscle mass and functional outcomes among older persons with HF.
  • ||||||||||  Trial completion date, Trial primary completion date:  Muscle Dysfunction in Patients with Haematological Diseases (clinicaltrials.gov) -  Nov 15, 2024   
    P=N/A,  N=216, Recruiting, 
    https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024530487, Registration number: CRD42024530487. Trial completion date: Dec 2023 --> May 2026 | Trial primary completion date: Dec 2022 --> Jun 2025